TASLY(600535) 国际金融报·2025-04-03 14:07Group 1 - The core point of the news is the completion of the equity transaction between China Resources Sanjiu and Tasly, marking a significant change in Tasly's ownership structure and management [1][5][6] - China Resources Sanjiu acquired 28% of Tasly's shares for approximately 6.212 billion yuan, while Tasly's controlling shareholder changed from the Yan family to China Resources [1][4] - Following the acquisition, several senior executives at Tasly resigned, indicating a major internal restructuring [1][2] Group 2 - Tasly, founded in 1994, has faced unstable performance and over-reliance on a single product, leading to its sale [3][5] - The company experienced a significant revenue decline of 31.43% in 2021, with a net profit drop of 110.8% in 2022, marking its first loss since going public [3][5] - In 2023, Tasly reported a slight revenue increase to 8.67 billion yuan, but revenue fell again in 2024 to 8.498 billion yuan [3][5] Group 3 - The acquisition is part of China Resources' strategy to expand its presence in the traditional Chinese medicine sector, having previously acquired other pharmaceutical companies [6][5] - The integration of Tasly is expected to enhance China Resources' capabilities in innovative Chinese medicine and cardiovascular products, creating potential synergies [5][6] - Industry experts anticipate that China Resources will continue to pursue mergers and acquisitions in the Chinese medicine sector, intensifying competition among leading companies [6][5]